Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2583829 | 1.00 | PPARA (0.55) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL30844631 | 1.00 | PPARA (0.55) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL30416417 | 1.00 | PPARA (0.55) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL28430225 | 1.00 | PPARA (0.55) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL15381001 | 0.90 | PPARA (0.48) | PPARACTSSPPARGTNFMDM4 | |
| SCHEMBL8749905 | 0.90 | MDM4 (0.51) | MDM4TP53MDM2CASP3 | |
| SCHEMBL13878600 | 0.88 | CTSS (0.59) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL30844644 | 0.88 | HDAC1 (0.52) | CTSSTNFMDM4TP53CASP3 | |
| SCHEMBL25444784 | 0.88 | SYK (0.53) | CTSSTNFMDM4TP53MDM2 | |
| SCHEMBL29902226 | 0.88 | SYK (0.53) | CTSSTNFMDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
| CN-111356456-A | 2-arylsulfonamido-iV-arylacetamide derived Stat3 inhibitor | 夏威夷大学 | 2020-06-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | PPARA 459/4885CTSS 1734/4885KLK7 4817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.